Home > Journals > Journal of Global Medical Education and Research

Journal of Global Medical Education and Research

Submit your article Read this Journals View all journals
Full Text (PDF)
Original Article

To Evaluate Functional Efficacy of Subconjunctival Bevacizumab in Cases of Corneal Neovascularization

Anirudh Singh

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Journal of Global Medical Education and Research 1(2):p 45-49, July-December 2024. | DOI: N/A

How Cite This Article:

Anirudh Singh/To Evaluate Functional Efficacy of Subconjunctival Bevacizumab in Cases of Corneal Neovascularization/ 2024;1(2): 45-49.

Timeline

Received : September 02, 2024         Accepted : November 15, 2024          Published : December 30, 2024

Abstract

Background:To evaluate functional efficacy of subconjunctival bevacizumab in cases of corneal neovascularization Design: Prospective comparative study Material & Methods: Fifty cases of corneal NV who are relatively resistant to all conventional modes of medical and surgical management were included in this prospective study conducted in our OPD. The conventional modes of medical treatment was more than 6 weeks of non-steroidal anti-inflammatory drugs and low potency steroids. A standard clinical proforma was filled in all cases for analytical study which included visual acuity recording, pre-injection digital photograph, recording of corneal vessel extent and diameter. All patients underwent subconjunctival bevacizumab 1.25mg (0.05 ml) under topical medication close to the corneal limbus near the corneal NV. The patients were followed up after 2 weeks and then again after 6 weeks. Results: The study of vessel extent showed that the vessels had regressed completely in 3 cases, while only marginal reduction in grades of vessel extent was seen in other categories (statistically significant p=0.000).The analysis of the vessel diameter and inflammation revealed that there was complete reduction of vessel in 3 cases, however only marginal reduction in grades of vessel diameter and inflammation was seen in other categories (statistically significant p=0.000). Analysis of visual acuity showed only marginal improvement in 7 cases out of 50(statistically significant p=0.000). Conclusions: This study concludes that subconjunctival bevacizumab (anti-VEGF agent) is a new and effective modality of reducing the corneal vascularization

References

No records found.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

The authors report no conflicts of interest in this work.

About this article

Cite this article

Anirudh Singh/To Evaluate Functional Efficacy of Subconjunctival Bevacizumab in Cases of Corneal Neovascularization/ 2024;1(2): 45-49.

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Received Accepted Published
September 02, 2024 November 15, 2024 December 30, 2024
DOI: N/A

Keywords

Subconjunctival bevacizumabCorneal vascularization

Article Level Metrics

Last Updated

Tuesday 20 October 2026, 02:18:33 (IST)

1102

Accesses

5
264
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received September 02, 2024
Accepted November 15, 2024
Published December 30, 2024

licence

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.

Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share